TGFB1 and secondary progressive multiple sclerosis: For instance, the cytokine TGF-β suppresses the expression of Eomesodermin in cytotoxic T cells in a mouse model.39 Furthermore, the treatment of mice with TGF-β ameliorates clinical symptoms of the EAE.40 However, a phase-1 trial of TGF-β2 in a small number of SPMS patients did not show an effect on EDSS or lesions in MRI but was associated with reversible nephrotoxicity.41